AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21696889 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 217
Study 21696889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 19404631 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 13
Study 19404631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16542198 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir soft-gel capsules 1200 mg three times daily for 3 days
Number of subjects: 38
Study 15307694 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Fructus Arctii Mixture (FAM)
Number of subjects: 31
Study 15307694 — intervention group
Group type: COMPARATOR
Intervention: Losartan (Control)
Number of subjects: 31
Study 11124359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg 9-methylene PGE(2) vaginal gel (meteneprost)
Number of subjects: 893
Study 11124359 — intervention group
Group type: COMPARATOR
Intervention: 600 microg oral PGE(1) (misoprostol)
Number of subjects: 893
Study 11124359 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 893
Study 11124359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral PGE(1) (misoprostol)
Number of subjects: 893
Study 11124359 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-methylene vaginal PGE(2) gel (meteneprost)
Number of subjects: 893
Study 9310802 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential administration (SQA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Number of subjects: 13
Study 9310802 — intervention group
Group type: COMPARATOR
Intervention: Continuous administration (CTA) of inhaled nitric oxide (NO) at 1, 3, and 6 ppm
Number of subjects: 13
Study 8379713 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of autologous platelet-rich plasma (PRP)
Number of subjects: 100
Study 8379713 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of autologous whole blood harvested immediately before cardiopulmonary bypass
Number of subjects: 100
Study 8379713 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative autologous blood conservation (control group)
Number of subjects: 100
Study 2876576 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI-118.551 (50 mg X 3)
Number of subjects: 18
Study 2876576 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-propranolol (80 mg X 3)
Number of subjects: 18
Study 2876576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (X 3)
Number of subjects: 18
Study 2876576 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI-118.551 and dl-propranolol
Number of subjects: 18
Study 31152196 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteral stent F4.7
Number of subjects: 181
Study 31152196 — intervention group
Group type: COMPARATOR
Intervention: Ureteral stent F6
Number of subjects: 181
Study 31152196 — intervention group
Group type: COMPARATOR
Intervention: Ureteral stent F7
Number of subjects: 181
Study 30460369 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B phototherapy and topical corticosteroid
Number of subjects: 18
Study 30460369 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroid only
Number of subjects: 18
Study 29158663 — intervention group
Group type: EXPERIMENTAL
Intervention: DA‐2802 (319 mg)
Number of subjects: 36
Study 29158663 — intervention group
Group type: COMPARATOR
Intervention: TDF (300 mg)
Number of subjects: 36
Study 25719692 — intervention group
Group type: EXPERIMENTAL
Intervention: MT10109L
Number of subjects: 168
Study 25719692 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 168
Study 23481084 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG)
Number of subjects: 570
Study 23481084 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 570
Study 21788624 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg
Number of subjects: 3488
Study 21788624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3488
Study 19406293 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic physiotherapy
Number of subjects: 65
Study 19406293 — intervention group
Group type: COMPARATOR
Intervention: Additional ward treatment
Number of subjects: 65
Study 19406293 — intervention group
Group type: COMPARATOR
Intervention: Water exercise
Number of subjects: 65
Study 16500346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP) with 4 mL of inseminate
Number of subjects: 276
Study 16500346 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine tuboperitoneal insemination (IUTPI) with 10 mL of inseminate
Number of subjects: 276
Study 15625998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cincinnati Prehospital Stroke Scale (CPSS) administered by laypersons over the telephone
Number of subjects: 70
Study 11583725 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg fluvastatin twice daily
Number of subjects: 834
Study 11583725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 834
Study 9741035 — intervention group
Group type: EXPERIMENTAL
Intervention: History of purging behavior (HP; N = 24)
Number of subjects: 63
Study 9741035 — intervention group
Group type: COMPARATOR
Intervention: No history of purging behavior (NHP; N = 39)
Number of subjects: 63
Study 8040674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS) 2 g/m2/d for 4 days IV plus mesna
Number of subjects: 173
Study 8040674 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (CARB) 560 mg/m2 IV over 1 hour
Number of subjects: 173
Study 8040674 — intervention group
Group type: EXPERIMENTAL
Intervention: Iproplatin (CHIP) 325 mg/m2 IV over 2 hours
Number of subjects: 173
Study 8040674 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (EPIR) 90 mg/m2 IV push
Number of subjects: 173
Study 8040674 — intervention group
Group type: COMPARATOR
Intervention: CECA (cisplatin 90 mg/m2 IV on day 1, etoposide 200 mg/m2 IV on day 3, cyclophosphamide 150 mg/m2/d orally on days 7 to 13, doxorubicin 35 mg/m2 IV on day 14)
Number of subjects: 173
Study 8040674 — intervention group
Group type: COMPARATOR
Intervention: HDP/VP/CA (cisplatin 40 mg/m2 IV on days 1 to 5 and etoposide 200 mg/m2 IV on days 2 to 4 alternating with cyclophosphamide 150 mg/m2/d orally on days 1 to 7 and doxorubicin 35 mg/m2 IV on day 8)
Number of subjects: 173
Study 2522265 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia (Group I)
Number of subjects: 16
Study 2522265 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced anaesthesia (Group II)
Number of subjects: 16
Study 30984974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (1 × 10^10 cfu/d)
Number of subjects: 24
Study 28259243 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 267
Study 25989985 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection with physiotherapy
Number of subjects: 177
Study 25989985 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo injection with physiotherapy
Number of subjects: 177
Study 25989985 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-and-see)
Number of subjects: 177
Study 23716501 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity program
Number of subjects: 1635
Study 23716501 — intervention group
Group type: COMPARATOR
Intervention: Successful aging health education program
Number of subjects: 1635
Study 22054337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored package of housing modifications (ventilation systems and central heating)
Number of subjects: 177
Study 22054337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored package)
Number of subjects: 177
Study 22054337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored package of housing modifications
Number of subjects: 177
Study 22054337 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored package of housing modifications for children with 'severe' asthma
Number of subjects: 177
Study 19234844 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine in 10 ml saline
Number of subjects: 20
Study 19234844 — intervention group
Group type: COMPARATOR
Intervention: 10 ml saline
Number of subjects: 20
Study 16896939 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 16
Study 16896939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium disc spacers by Weber
Number of subjects: 267
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium disc spacers by Intromed
Number of subjects: 267
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonium spacers by AcroMed
Number of subjects: 267
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: AcoMed, Medinorm, and Intromed titanium spacers
Number of subjects: 267
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium cage Cespace by Aesculap
Number of subjects: 267
Study 15340803 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEK spacer by Intromed
Number of subjects: 267
Study 10770452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/day
Number of subjects: 10
Study 10770452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/day
Number of subjects: 10
Study 10770452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 150 mg/day
Number of subjects: 10
Study 10770452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10770452 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg orally
Number of subjects: 10
Study 9125795 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day prednisone
Number of subjects: 0
Study 9125795 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified fish oil concentrate (Omacor®)
Number of subjects: 0
Study 9125795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2015732 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine administration
Number of subjects: 5
Study 6832203 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg administered preoperatively
Number of subjects: 50
Study 6832203 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 1000 mg administered postoperatively
Number of subjects: 50
Study 31407353 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (1 mg per day for 1 month)
Number of subjects: 20
Study 31407353 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NSPT and placebo capsules for 1 month)
Number of subjects: 20
Study 30066262 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based approach
Number of subjects: 0
Study 30066262 — intervention group
Group type: EXPERIMENTAL
Intervention: Design-based approach
Number of subjects: 0
Study 28478622 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan pads
Number of subjects: 15
Study 28478622 — intervention group
Group type: COMPARATOR
Intervention: Gauze pads
Number of subjects: 15
Study 24964358 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 250
Study 24964358 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted protease inhibitors (PI/r)
Number of subjects: 250
Study 23591103 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin-A injections
Number of subjects: 20
Study 23591103 — intervention group
Group type: COMPARATOR
Intervention: Suction-curettage
Number of subjects: 20
Study 21257146 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%
Number of subjects: 178
Study 21257146 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 178
Study 19481566 — intervention group
Group type: EXPERIMENTAL
Intervention: Children
Number of subjects: 0
Study 19481566 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 0
Study 19481566 — intervention group
Group type: COMPARATOR
Intervention: Both children and adults
Number of subjects: 0
Study 16398793 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused smoking cessation intervention
Number of subjects: 363
Study 16398793 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal-focused smoking cessation intervention
Number of subjects: 363
Study 16398793 — intervention group
Group type: COMPARATOR
Intervention: Control group (no smoking cessation advice)
Number of subjects: 363
Study 15058848 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 152
Study 15058848 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 152
Study 11112196 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (1.5 x 10(6) KIU)
Number of subjects: 60
Study 11112196 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 60
Study 9424326 — intervention group
Group type: EXPERIMENTAL
Intervention: One-cycle cryosurgery
Number of subjects: 217
Study 9424326 — intervention group
Group type: EXPERIMENTAL
Intervention: Second cycle of cryosurgery
Number of subjects: 217
Study 9424326 — intervention group
Group type: EXPERIMENTAL
Intervention: Double freeze-thaw cycle
Number of subjects: 217
Study 1644456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone biopsy at the time of surgery
Number of subjects: 81
Study 1644456 — intervention group
Group type: COMPARATOR
Intervention: Previous study (20 years ago)
Number of subjects: 81
Study 1644456 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological screening and measurement of serum bone biochemistry
Number of subjects: 81
Study 1644456 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologically detectable osteoporosis
Number of subjects: 81
Study 6369348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined medication of 150 mg Chlorimipramine and 9 mg p.d. Haloperidol (given over six days)
Number of subjects: 20
Study 6369348 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study 2959232 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg p.o.)
Number of subjects: 13
Study 2959232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28755054 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI features predictive of EGFR expression level
Number of subjects: 270
Study 26660148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 191
Study 26660148 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 191
Study 24839882 — intervention group
Group type: EXPERIMENTAL
Intervention: JASP+EMT+SGD
Number of subjects: 61
Study 24839882 — intervention group
Group type: COMPARATOR
Intervention: JASP+EMT
Number of subjects: 61
Study 24839882 — intervention group
Group type: EXPERIMENTAL
Intervention: JASP+EMT+SGD (adaptive intervention)
Number of subjects: 61
Study 23237817 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified tumescent solution
Number of subjects: 10
Study 23237817 — intervention group
Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 10
Study 20544159 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional splint used during activities of daily living for 180 days
Number of subjects: 40
Study 20544159 — intervention group
Group type: COMPARATOR
Intervention: Control group used the splint only during evaluations for the first 90 days and during activities of daily living for the following 90 days
Number of subjects: 40
Study 20544159 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional splint
Number of subjects: 40
Study 18656872 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transducer with ultrasound stimulation (Exogen 2000)
Number of subjects: 101
Study 18656872 — intervention group
Group type: COMPARATOR
Intervention: Placebo transducer
Number of subjects: 101
Study 16083306 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD) for three weeks
Number of subjects: 14
Study 16083306 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 14
Study 16083306 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-Low-Calorie Diet (VLCD)
Number of subjects: 14
Study 12797711 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based (WB) format
Number of subjects: 75
Study 12797711 — intervention group
Group type: COMPARATOR
Intervention: Paper (P) format
Number of subjects: 75
Study 12797711 — intervention group
Group type: COMPARATOR
Intervention: Touch Screen (TS) format
Number of subjects: 75
Study 10785529 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-help leaflet offering cognitive-behavioural guidance
Number of subjects: 106
Study 8899256 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg depot‐medroxyprogesterone acetate (DMPA), intramuscularly on days 42 + 1 and 126 + 1 postpartum
Number of subjects: 22
Study 8899256 — intervention group
Group type: COMPARATOR
Intervention: Control group (infants of mothers who did not receive DMPA)
Number of subjects: 22
Study 2060336 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 0
Study 2060336 — intervention group
Group type: COMPARATOR
Intervention: Heated Humidifier (HH)
Number of subjects: 0
Study 2060336 — intervention group
Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 0
Study 2060336 — intervention group
Group type: COMPARATOR
Intervention: HH
Number of subjects: 0
Study 6418690 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% sodium cromoglycate (SC) solution t.i.d. by means of a home nebulizer
Number of subjects: 22
Study 6418690 — intervention group
Group type: COMPARATOR
Intervention: 2 ml placebo (water) nebulization
Number of subjects: 22
Study 30122646 — intervention group
Group type: EXPERIMENTAL
Intervention: qHPV vaccine
Number of subjects: 3006
Study 29449102 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue
Number of subjects: 71
Study 29449102 — intervention group
Group type: COMPARATOR
Intervention: Filling gelfoam
Number of subjects: 71
Study 27564281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided csPCNL (group A)
Number of subjects: 51
Study 27564281 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopically guided csPCNL (group B)
Number of subjects: 51
Study 24641742 — intervention group
Group type: EXPERIMENTAL
Intervention: Place and active hold exercises
Number of subjects: 54
Study 24641742 — intervention group
Group type: COMPARATOR
Intervention: Controlled passive mobilization (modified Kleinert)
Number of subjects: 54
Study 23213957 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) - 8-week speed training program, 3 days a week
Number of subjects: 30
Study 23213957 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no intervention
Number of subjects: 30
Study 23213957 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (EG) - 8-week speed training program
Number of subjects: 30
Study 19671542 — intervention group
Group type: COMPARATOR
Intervention: guaiac-based faecal occult blood test (gFOBT)
Number of subjects: 15011
Study 19671542 — intervention group
Group type: COMPARATOR
Intervention: immunochemical faecal occult blood test (FIT)
Number of subjects: 15011
Study 19671542 — intervention group
Group type: COMPARATOR
Intervention: flexible sigmoidoscopy (FS)
Number of subjects: 15011
Study 18042655 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable feedback group (VAR)
Number of subjects: 30
Study 18042655 — intervention group
Group type: COMPARATOR
Intervention: Constant feedback group (CON)
Number of subjects: 30
Study 15860542 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized least squares and maximum likelihood methods for estimating piecewise density function and examination sensitivity
Number of subjects: 0
Study 15860542 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized least squares and maximum likelihood methods
Number of subjects: 0
Study 11154865 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 0
Study 11154865 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine
Number of subjects: 0
Study 11154865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9455696 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation (30 mg per day for 1 month)
Number of subjects: 14
Study 9455696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 1 month)
Number of subjects: 14
Study 9455696 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental exercise to exhaustion
Number of subjects: 14
Study 9455696 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 14
Study 7834163 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidic urine conditions
Number of subjects: 0
Study 7834163 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline urine conditions
Number of subjects: 0
Study 3280304 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing the dose until the level reached and stayed at the therapeutic range (study arm B)
Number of subjects: 79
Study 3280304 — intervention group
Group type: COMPARATOR
Intervention: Keeping the level in the subtherapeutic range (study arm A)
Number of subjects: 79
Study 31765047 — intervention group
Group type: EXPERIMENTAL
Intervention: Linked color imaging (LCI)
Number of subjects: 84
Study 31765047 — intervention group
Group type: COMPARATOR
Intervention: White-light imaging (WLI)
Number of subjects: 84
Study 31115626 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite criteria using tumor size < 6.0 cm, tumor number < 8, alpha-fetoprotein < 465 ng/mL, TBRmax < 2.8
Number of subjects: 239
Study 31115626 — intervention group
Group type: COMPARATOR
Intervention: Conventional recipient selection criteria
Number of subjects: 239
Study 27472957 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 82
Study 27472957 — intervention group
Group type: EXPERIMENTAL
Intervention: OrthoMTA
Number of subjects: 82
Study 27472957 — intervention group
Group type: EXPERIMENTAL
Intervention: RetroMTA
Number of subjects: 82
Study 23553187 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeldicks Light Training Programme
Number of subjects: 66
Study 23977105 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour shift (24 hS)
Number of subjects: 17
Study 23977105 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 17